It is common practice in the case of Turner syndrome (TS) to treat short stature with GH treatment and to induce puberty with estrogens at an age as close to normal puberty as possible. This approach in most cases leads to a height in the normal range in childhood, adolescence, and adulthood in TS. Little data is available, however, on its effect on psychosocial functioning. In the present study, we evaluated psychosocial functioning in a group of 50 women with TS, after reaching final height in two multicenter GH trials. Thirty-six girls participated in a randomized dose-response study from mean (SEM) age 6.8 (0.4) years, and 14 girls participated in a frequency-response study from age 13.2 (0.4) years. After discontinuation of long-term GH treatment, these 50 girls were evaluated for psychosocial functioning at a mean age of 18.8 (0.3) years. GH was given in a dosage of 4 IU/m2/day (∼0.045 mg/kg/day), 6 IU/m2/day, or 8 IU/m2/day. After a mean GH treatment duration of 7.1 (0.4) years, mean final height (ref. normal girls) was FH1.2 (0.2) SD score. Behavioral problem scores (Achenbach) of the TS women were comparable to normal Dutch peers. Although self-perception (Harter total scale: p < 0.01), and bodily attitude (Baardman: p < 0.05) was significantly less positive than for their normal Dutch peers, we found no evidence of depression. TS women rated their family functioning higher than their Dutch peers (p < 0.0001), and had a slightly different coping pattern. These results show that even after reaching a height in most cases within the normal range and puberty induction at a pubertal age, some women with TS still experience psychosocial problems. It is likely, however, that GH and estrogen treatment improved psychosocial functioning. Long-term follow-up of these GH-treated patients will allow an evaluation of their life achievements.

Keywords:
Growth hormone therapy, GH trials, psychological evaluation, Turner syndrome, Turner syndrome, final height, Turner syndrome, short stature
1.
Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Hokken-Koelega AC, Waelkens JJ, Massa GG, Vulsma T, Gerver WJ, Reeser HM, Delemarre-van de Waal HE, Jansen M, Drop SL: Final height in girls with Turner’s syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone. Arch Dis Child 1999;80:36–41.
2.
Cacciari E, Mazzanti L: Final height of patients with Turner’s syndrome treated with growth hormone (GH): Indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome. J Clin Endocrinol Metab 1999;84:4510–4515.
3.
Johnston DI, Betts P, Dunger D, Barnes N, Swift PG, Buckler JM, Butler GE: A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: Near final height analysis. Arch Dis Child 2001;84:76–81.
4.
Quigley CA, Crowe BJ, Anglin DG, Chipman JJ: Growth hormone and low dose estrogen in Turner syndrome: Results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002;87:2033–2041.
5.
Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL: Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119–1125.
6.
Rovet JF: Behavioural manifestations of Turner syndrome in children: A unique phenotype? Turner syndrome in a life-span perspective: Research and clinical aspects. 4th International Symposium on Turner Syndrome, Gothenburg, Sweden, May 18–21, 1995. Amsterdam, Elsevier Science, 1995.
7.
Ross JL, McCauley E, Roeltgen D, Long L, Kushner H, Feuillan P, Cutler GB Jr: Self-concept and behavior in adolescent girls with Turner syndrome: Potential estrogen effects. J Clin Endocrinol Metab 1996;81:926–931.
8.
Simis KJ, Verhulst FC, Koot HM: Body image, psychosocial functioning, and personality: How different are adolescents and young adults applying for plastic surgery? J Child Psychol Psychiatry 2001;42:669–678.
9.
Standard Occupational Classification 1992. The Hague, Central Bureau for Statistics, 1993, p 185.
10.
Ferdinand RF, Verhulst FC, Wiznitzer M: Continuity and change of self-reported problem behaviors from adolescence into young adulthood. J Am Acad Child Adolesc Psychiatry 1995;34:680–690.
11.
Verhulst F, van der Ende J, Koot H: Manual for the Youth Self-Report (YSR). Rotterdam, Child and Adolescent Psychiatry, Sophia Children’s Hospital/ University Hospital Rotterdam/ Erasmus University Rotterdam, 1997, p 233.
12.
Achenbach TM: Manual for the CBCL/4-18 and 1991 Profile. Burlington, University of Vermont, Department of Psychiatry, 1991.
13.
Achenbach TM: Manual for the Youth Self-Report and 1991 Profile. Burlington, University of Vermont, Department of Psychiatry, 1991.
14.
Achenbach T: Manual for the Young Adult Self-Report and Young Adult Behavior Checklist. Burlington, University of Vermont, Department of Psychiatry, 1997.
15.
Harter S: Manual of the Self-Perception Profile for Children. Denver, University of Denver, 1985.
16.
Harter S: Manual of the Self-Perception Profile for Adolescents. Denver, University of Denver, 1986.
17.
Kovacs M: Children’s Depression Inventory. New York, Multi-Health Systems, Inc, 1992.
18.
Baardman I: Ingebeelde lelijkheid. Amsterdam, Department of Psychology and Pedagogy, Free University, 1989.
19.
Byles J, Byrne C, Boyle MH, Offord DR: Ontario Child Health Study: Reliability and Validity of the General Functioning Subscale of the McMaster Family Assessment Device. Fam Proc 1988;27:97–104.
20.
Wenniger FM: Cross-national validity of dimensions of the family functioning: First experiences with the Dutch version of the McMaster Family Assessment Device (FAD). 1993;14:769–781.
21.
Schreurs PJG, van de Willige G, Tellegen B, Graus GMH: De Utrechtse Coping Lijst: UCL, Omgaan met problemen en gebeurtenissen, Herziene handleiding 1993. Lisse, Swets & Zettinger, 1993, p 49.
22.
Bijstra JO, Jackson S, Bosma HA: De Utrechtse Coping Lijst voor Adolescenten. Kind Adolesc 1994;15:98–109.
23.
Schaufeli W, Dierendonck D: De betrouwbaarheid en validiteit van de Utrechtse Coping Lijst, een longitudinaal onderzoek bij schoolverlaters. Gedrag Gezond 1992;20:38–45.
24.
McCauley E, Ito J, Kay T: Psychosocial functioning in girls with Turner’s syndrome and short stature: Social skills, behavior problems, and self-concept. J Am Acad Child Psychiatry 1986;25:105–112.
25.
Lagrou K, Xhrouet-Heinrichs D, Heinrichs C, Craen M, Chanoine JP, Malvaux P, Bourguignon JP: Age-related perception of stature, acceptance of therapy, and psychosocial functioning in human growth hormone-treated girls with Turner’s syndrome. J Clin Endocrinol Metab 1998;83:1494–1501.
26.
Rovet J, Holland J: Psychological aspects of the Canadian randomized controlled trial of human growth hormone and low-dose ethinyl oestradiol in children with Turner syndrome. The Canadian Growth Hormone Advisory Group. Horm Res 1993;39:60–64.
27.
Siegel PT, Clopper R, Stabler B: The psychological consequences of Turner syndrome and review of the National Cooperative Growth Study psychological substudy. Pediatrics 1998;102:488–491.
28.
McCauley E, Ross JL, Kushner H, Cutler G Jr: Self-esteem and behavior in girls with Turner syndrome. J Dev Behav Pediatr 1995;16:82–88.
29.
Boman UW, Bryman I, Halling K, Moller A: Women with Turner syndrome: Psychological well-being, self-rated health and social life. J Psychosom Obstet Gynaecol 2001;22:113–122.
30.
Lawrence K, Kuntsi J, Coleman M, Campbell R, Skuse D: Face and emotion recognition deficits in Turner syndrome: A possible role for X-linked genes in amygdala development. Neuropsychology 2003;17:39–49.
31.
Nijhuis-van der Sanden MW, Smits-Engelsman BC, Eling PA, Nijhuis BJ, Van Galen GP: Low elementary movement speed is associated with poor motor skill in Turner’s syndrome. Dev Neuropsychol 2002;22:643–670.
32.
Downey J, Ehrhardt AA, Gruen R, Bell JJ, Morishima A: Psychopathology and social functioning in women with Turner syndrome. J Nerv Ment Dis 1989;177:191–201.
33.
Delooz J, Van den Berghe H, Swillen A, Kleczkowska A, Fryns JP: Turner syndrome patients as adults: A study of their cognitive profile, psychosocial functioning and psycho pathological findings. Genet Couns 1993;4:169–179.
34.
Rickert VI, Hassed SJ, Hendon AE, Cunniff C: The effects of peer ridicule on depression and self-image among adolescent females with Turner syndrome. J Adolesc Health 1996;19:34–38.
35.
Pavlidis K, McCauley E, Sybert VP: Psychosocial and sexual functioning in women with Turner syndrome. Clin Genet 1995;47:85–89.
36.
Sartorio A, Conti A, Molinari E, Riva G, Morabito F, Faglia G: Growth, growth hormone and cognitive functions. Horm Res 1996;45:23–29.
37.
Wide Boman U, Moller A, Albertsson-Wikland K: Psychological aspects of Turner syndrome. J Psychosom Obstet Gynaecol 1998;19:1–18.
38.
Downey J, Ehrhardt AA, Gruen R, Morishima A, Bell J: Turner syndrome versus constitutional short stature: Psychopathology and reactions to height; in Stabler B, Underwood LE (eds): Slow Grows the Child: Psychological Aspects of Growth Delay. Mahwah/NJ, Lawrence Erlbaum Assoc, Inc, 1986, pp 123–138.
39.
Van Pareren Y, Duivenvoorden H, Slijper F, Koot H, Hokken-Koelega A: Intelligence and psychosocial functioning during long-term GH therapy in children born small for gestational age. J Clin Endocrinol Metab 2004;89:5295–5302.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.